Director/PDMR Shareholding

RNS Number : 7445Y
Genedrive PLC
07 December 2017
 

Notification and public disclosure of transactions by persons discharging

managerial responsibilities and persons closely associated with them

 

genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient molecular diagnostics company, announces that it has granted share options ("Options") to certain of its directors and senior management to acquire a total of 156,087 ordinary shares of 1.5p each in the capital of the Company under the Company's newly adopted 2017 Share Option Scheme.

 

The Options have been granted with an exercise price equal to the close price on the day before grant and vest after a period of three years. The Options will vest after 3 years only if certain performance criteria are met.  The Options are exercisable over the period of 10 years from the date of grant.

 

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

 

1.         

Details of the person discharging managerial responsibilities / person closely associated

a.         

Name

1.   Gordon Powell

2.   Gino Miele

3.   Nancy Neilson

 

2.         

Reason for the notification

a.         

Position/status

1.   Commercial Director

2.   R&D Director

3.   Quality Assurance Director

 

a.         

Initial notification

/Amendment

Initial notification

3.  

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.         

Name

genedrive plc

b.         

LEI

213800ZYODIRZ87Y4K14

4.         

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.         

Description of the

Financial instrument, type

of instrument

Identification code

Options over ordinary shares of 1.5 pence each

b.         

Nature of the transaction

Grant of options pursuant to and in accordance with the terms of the Company's Share Option Scheme dated 29 November 2017.

c.         

Price(s) and volume(s)

 

Price(s)

 

Option price(s)

Volume(s)

Gordon Powell

36.0p

88,063

Gino Miele

36.0p

43,024

Nancy Neilson

36.0p

25,000

d.         

Aggregated information

·      Aggregated volume

·      Price

 

 

N/A

 

e.         

Date of the transaction

2017-12-07; UTC time

f.         

Place of the transaction

Outside trading venue - shares to be admitted to AIM market of London Stock Exchange plc on exercise of options

 

For further details please contact:

genedrive plc

+44 (0)161 989 0245

David Budd: CEO


Matthew Fowler: CFO


Peel Hunt LLP

+44 (0)207 418 8900

James Steel


Oliver Jackson


Consilium Strategic Communications

+44 (0)203 709 5700

Chris Gardner


Matthew Neal


Laura Thornton


genedrive@consilium-comms.com


 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHEAKAXEAKXFFF

Companies

Genedrive (GDR)
UK 100

Latest directors dealings